<DOC>
	<DOCNO>NCT02421770</DOCNO>
	<brief_summary>Oral lichen planus ( OLP ) chronic inflammatory mucocutaneous disease characterize outbreaks flare . It affect 0.2-1.9 % population . Although etiology unknown , pathogenesis OLP know involve immune disorder , epithelial damage cause cytotoxic CD8 + lymphocytes . Clinically , disease characterize different type lesion - papular , reticular form plaque - alternate erosive and/or ulcerative area . A variety treatment propose OLP : topical systemic corticosteroid , cyclosporine , retinoids , azathioprine , tacrolimus , pimecrolimus , photochemotherapy surgery . Patients symptomatic OLP often require intensive therapy reduce sign symptom . The disease produce considerable morbidity alter patient quality life , particularly presence ulcerative lesion . There fully resolutive effective treatment - management strategy focus use drug counter tissue inflammation underlie immunological mechanism . The main inconvenience treatment represent side effect usually produce .</brief_summary>
	<brief_title>Chamaemelum Nobile 2 % Versus Placebo Topic Gel Treat Oral Lichen Planus</brief_title>
	<detailed_description>The purpose study evaluate Chamaemelum Nobile use treatment oral lichen planus . This could useful Chamaemelum Nobile report side effect hence use place steroid commonly use condition many report adverse effect .</detailed_description>
	<mesh_term>Lichen Planus , Oral</mesh_term>
	<mesh_term>Lichen Planus</mesh_term>
	<criteria>1 . Patients clinically &amp; histopathologically diagnose suffer oral lichen planus . 2 . Patients symptoms i.e . pain and/or burn sensation secondary oral lichen planus . 3 . Patients treatment . In case , treatment stop washout period two week give . 1 . Patients suffer systemic disease/s like 2 . Patients mucosal disease skin disease may associate oral lesion . 3 . Patients drug therapy may cause lichen planus like lesion . 4 . Patients findings physical mental abnormality , would interfere affected study procedure . 5 . Patients know allergy contraindication study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>